Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Status:
Terminated
Trial end date:
2020-11-06
Target enrollment:
Participant gender:
Summary
Open-label, randomized, controlled, phase 3 safety and efficacy registration trial.
Subjects will be randomized at baseline to the standard of care for first-line treatment of
glioblastoma plus Trans Sodium Crocetinate (TSC) or the standard of care.
The standard of care for GBM will consist of temozolomide plus radiation therapy for 6 weeks
followed by 28 days of rest followed by 6 cycles of post-radiation temozolomide treatment.